Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype.

Applebaum MA, Barr EK, Karpus J, Nie J, Zhang Z, Armstrong AE, Uppal S, Sukhanova M, Zhang W, Chlenski A, Salwen HR, Wilkinson E, Dobratic M, Grossman R, Godley LA, Stranger BE, He C, Cohn SL.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00402. Epub 2019 May 16.

PMID:
31179414
2.

Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.

Chlenski A, Park C, Dobratic M, Salwen HR, Budke B, Park JH, Miller R, Applebaum MA, Wilkinson E, Nakamura Y, Connell PP, Cohn SL.

Mol Cancer Ther. 2019 Mar;18(3):507-516. doi: 10.1158/1535-7163.MCT-18-0819. Epub 2019 Jan 23.

PMID:
30674566
3.

Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids.

Chlenski A, Dobratic M, Salwen HR, Applebaum M, Guerrero LJ, Miller R, DeWane G, Solomaha E, Marks JD, Cohn SL.

Oncotarget. 2016 Nov 22;7(47):77696-77706. doi: 10.18632/oncotarget.12773.

4.

Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients.

Applebaum MA, Jha AR, Kao C, Hernandez KM, DeWane G, Salwen HR, Chlenski A, Dobratic M, Mariani CJ, Godley LA, Prabhakar N, White K, Stranger BE, Cohn SL.

Oncotarget. 2016 Nov 22;7(47):76816-76826. doi: 10.18632/oncotarget.12713.

5.

Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounterâ„¢ system.

Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage PE, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, London WB, Pytel P, Maclean KH, Cohn SL.

Mol Oncol. 2014 May;8(3):669-78. doi: 10.1016/j.molonc.2014.01.010. Epub 2014 Jan 31.

6.

Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.

Lu Z, Tian Y, Salwen HR, Chlenski A, Godley LA, Raj JU, Yang Q.

Anticancer Drugs. 2013 Jun;24(5):484-93. doi: 10.1097/CAD.0b013e32835ffdbb.

7.

Valproic acid shows a potent antitumor effect with alteration of DNA methylation in neuroblastoma.

Gu S, Tian Y, Chlenski A, Salwen HR, Lu Z, Raj JU, Yang Q.

Anticancer Drugs. 2012 Nov;23(10):1054-66.

8.

Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma.

Ostler KR, Yang Q, Looney TJ, Zhang L, Vasanthakumar A, Tian Y, Kocherginsky M, Raimondi SL, DeMaio JG, Salwen HR, Gu S, Chlenski A, Naranjo A, Gill A, Peddinti R, Lahn BT, Cohn SL, Godley LA.

Cancer Res. 2012 Sep 15;72(18):4714-23. doi: 10.1158/0008-5472.CAN-12-0886. Epub 2012 Jul 18.

9.

Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth.

Kakodkar NC, Peddinti RR, Tian Y, Guerrero LJ, Chlenski A, Yang Q, Salwen HR, Maitland ML, Cohn SL.

Pediatr Blood Cancer. 2012 Oct;59(4):642-7. doi: 10.1002/pbc.24004. Epub 2011 Dec 6.

PMID:
22147414
10.

Secreted protein acidic and rich in cysteine is a matrix scavenger chaperone.

Chlenski A, Guerrero LJ, Salwen HR, Yang Q, Tian Y, Morales La Madrid A, Mirzoeva S, Bouyer PG, Xu D, Walker M, Cohn SL.

PLoS One. 2011;6(9):e23880. doi: 10.1371/journal.pone.0023880. Epub 2011 Sep 16.

11.

The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth.

Kakodkar NC, Peddinti R, Kletzel M, Tian Y, Guerrero LJ, Undevia SD, Geary D, Chlenski A, Yang Q, Salwen HR, Cohn SL.

Pediatr Blood Cancer. 2011 Jan;56(1):164-7. doi: 10.1002/pbc.22639.

12.

Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines.

Yang Q, Tian Y, Ostler KR, Chlenski A, Guerrero LJ, Salwen HR, Godley LA, Cohn SL.

BMC Cancer. 2010 Jun 14;10:286. doi: 10.1186/1471-2407-10-286.

13.

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

Chlenski A, Guerrero LJ, Peddinti R, Spitz JA, Leonhardt PT, Yang Q, Tian Y, Salwen HR, Cohn SL.

Mol Cancer. 2010 Jun 4;9:138. doi: 10.1186/1476-4598-9-138.

14.

Presence of cancer-associated fibroblasts inversely correlates with Schwannian stroma in neuroblastoma tumors.

Zeine R, Salwen HR, Peddinti R, Tian Y, Guerrero L, Yang Q, Chlenski A, Cohn SL.

Mod Pathol. 2009 Jul;22(7):950-8. doi: 10.1038/modpathol.2009.52. Epub 2009 May 1.

15.

Prominent microvascular proliferation in clinically aggressive neuroblastoma.

Peddinti R, Zeine R, Luca D, Seshadri R, Chlenski A, Cole K, Pawel B, Salwen HR, Maris JM, Cohn SL.

Clin Cancer Res. 2007 Jun 15;13(12):3499-506.

16.

Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome.

Yang Q, Kiernan CM, Tian Y, Salwen HR, Chlenski A, Brumback BA, London WB, Cohn SL.

Clin Cancer Res. 2007 Jun 1;13(11):3191-7.

17.

Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.

Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR, Henkin J, Cohn SL.

Cancer Res. 2007 Feb 15;67(4):1716-24.

18.

SPARC enhances tumor stroma formation and prevents fibroblast activation.

Chlenski A, Guerrero LJ, Yang Q, Tian Y, Peddinti R, Salwen HR, Cohn SL.

Oncogene. 2007 Jul 5;26(31):4513-22. Epub 2007 Jan 29.

PMID:
17260013
19.

SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix.

Chlenski A, Liu S, Guerrero LJ, Yang Q, Tian Y, Salwen HR, Zage P, Cohn SL.

Int J Cancer. 2006 Jan 15;118(2):310-6.

20.

'Cross-talk' between Schwannian stroma and neuroblasts promotes neuroblastoma tumor differentiation and inhibits angiogenesis.

Liu S, Tian Y, Chlenski A, Yang Q, Salwen HR, Cohn SL.

Cancer Lett. 2005 Oct 18;228(1-2):125-31. Review.

PMID:
15935552
21.

Cross-talk between Schwann cells and neuroblasts influences the biology of neuroblastoma xenografts.

Liu S, Tian Y, Chlenski A, Yang Q, Zage P, Salwen HR, Crawford SE, Cohn SL.

Am J Pathol. 2005 Mar;166(3):891-900.

22.

Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.

Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR, Liu S, Chlenski A, Cohn SL.

Clin Cancer Res. 2004 Dec 15;10(24):8493-500.

23.
24.

Methylation-associated silencing of the heat shock protein 47 gene in human neuroblastoma.

Yang Q, Liu S, Tian Y, Hasan C, Kersey D, Salwen HR, Chlenski A, Perlman EJ, Cohn SL.

Cancer Res. 2004 Jul 1;64(13):4531-8.

25.

MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma.

Manohar CF, Bray JA, Salwen HR, Madafiglio J, Cheng A, Flemming C, Marshall GM, Norris MD, Haber M, Cohn SL.

Oncogene. 2004 Jan 22;23(3):753-62.

PMID:
14737110
26.

Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.

Yang QW, Liu S, Tian Y, Salwen HR, Chlenski A, Weinstein J, Cohn SL.

Cancer Res. 2003 Oct 1;63(19):6299-310.

27.

SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis.

Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J, Cohn SL.

Cancer Res. 2002 Dec 15;62(24):7357-63.

28.

Antiangiogenic therapy inhibits human neuroblastoma growth.

Katzenstein HM, Salwen HR, Nguyen NN, Meitar D, Cohn SL.

Med Pediatr Oncol. 2001 Jan;36(1):190-3.

PMID:
11464880
29.

MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.

Cohn SL, London WB, Huang D, Katzenstein HM, Salwen HR, Reinhart T, Madafiglio J, Marshall GM, Norris MD, Haber M.

J Clin Oncol. 2000 Nov 1;18(21):3604-13.

PMID:
11054433
30.

Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden.

Katzenstein HM, Rademaker AW, Senger C, Salwen HR, Nguyen NN, Thorner PS, Litsas L, Cohn SL.

Clin Cancer Res. 1999 Dec;5(12):4273-8.

31.
32.

Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.

Manohar CF, Salwen HR, Brodeur GM, Cohn SL.

Genes Chromosomes Cancer. 1995 Nov;14(3):196-203.

PMID:
8589036
33.

The biological effects of antisense N-myc expression in human neuroblastoma.

Schmidt ML, Salwen HR, Manohar CF, Ikegaki N, Cohn SL.

Cell Growth Differ. 1994 Feb;5(2):171-8.

34.

Retinoic acid induced expression of homeobox genes in human neuroblastoma cells.

Manohar CF, Salwen HR, Furtado MR, Cohn SL.

Prog Clin Biol Res. 1994;385:229-35. No abstract available.

PMID:
7972214
35.

Evidence for molecular heterogeneity in human ganglioneuroblastoma.

Schmidt ML, Salwen HR, Chagnovich D, Bauer KD, Crawford SE, Cohn SL.

Pediatr Pathol. 1993 Nov-Dec;13(6):787-96.

PMID:
8108298
36.

Hox gene expression in differentiating human neuroblastoma cells.

Manohar CF, Furtado MR, Salwen HR, Cohn SL.

Biochem Mol Biol Int. 1993 Jul;30(4):733-41.

PMID:
8104620
37.

Differential expression of N-myc in phenotypically distinct subclones of a human neuroblastoma cell line.

Foley J, Cohn SL, Salwen HR, Chagnovich D, Cowan J, Mason KL, Parysek LM.

Cancer Res. 1991 Dec 1;51(23 Pt 1):6338-45.

38.

Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma.

Cohn SL, Rademaker AW, Salwen HR, Franklin WA, Gonzales-Crussi F, Rosen ST, Bauer KD.

Am J Pathol. 1990 May;136(5):1043-52.

39.

Characterization of a novel myeloma cell line, MM.1.

Goldman-Leikin RE, Salwen HR, Herst CV, Variakojis D, Bian ML, Le Beau MM, Selvanayagan P, Marder R, Anderson R, Weitzman S, et al.

J Lab Clin Med. 1989 Mar;113(3):335-45.

PMID:
2926241
40.

Establishment and characterization of a neuroendocrine skin carcinoma cell line.

Rosen ST, Gould VE, Salwen HR, Herst CV, Le Beau MM, Lee I, Bauer K, Marder RJ, Andersen R, Kies MS, et al.

Lab Invest. 1987 Mar;56(3):302-12.

PMID:
3546933
41.

Monoclonal antibody 44-3A6 as a probe for a novel antigen found on human lung carcinomas with glandular differentiation.

Radosevich JA, Ma YX, Lee I, Salwen HR, Gould VE, Rosen ST.

Cancer Res. 1985 Nov;45(11 Pt 2):5808-12.

42.

Carnosinase deficiency: a new variant with high residual activity.

Fleisher LD, Rassin DK, Wisniewski K, Salwen HR.

Pediatr Res. 1980 Apr;14(4 Pt 1):269-71.

PMID:
7375183
43.

Argininosuccinic aciduria: prenatal studies in a family at risk.

Fleisher LD, Rassin DK, Desnick RJ, Salwen HR, Rogers P, Bean M, Gaull GE.

Am J Hum Genet. 1979 Jul;31(4):439-45.

44.

De novo trisomy 9pter leads to q13.

Kardon NB, Salwen HR, Krauss MA, Davis JG, Jenkins EC.

Hum Genet. 1977 Jun 30;37(2):149-53.

PMID:
885535

Supplemental Content

Loading ...
Support Center